RecruitingNCT07627074

Weight Loss in Adults Using Semaglutide (Real-world Study)

Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study


Sponsor

Novo Nordisk A/S

Enrollment

35,000 participants

Start Date

May 12, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Semaglutide for people with obesity and overweight. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSemaglutide

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.


Locations(2)

Novo Nordisk Investigational Site

Seattle, Washington, United States

Novo Nordisk Investigational Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07627074


Related Trials